Monoclonal antibodies: Immunogenicity and side effect profiles

Medication	Target	Side effect profile	Origin	Immunogenicity—risk of hypersensitivity
avelumab	Immune system or checkpoint	Autoimmune—any system can be affected	Human	Lower
obinituzumab	Tumour antigen	Dependent on targeted receptor	Humanised	Moderate
rituximab	Tumour antigen	Dependent on targeted receptor	Chimeric	High
****gemtuzumab ozogamicin**	Tumour antigen	Dependent on targeted receptor	Humanised	Moderate
panitumumab	Tumour antigen	Dependent on targeted receptor	Human	Lower
dinutuximab	Tumour antigen	Dependent on targeted receptor	Chimeric	High
ipilimumab	Immune system or checkpoint	Autoimmune—any system can be affected	Human	Lower
alemtuzumab	Tumour antigen	Dependent on targeted receptor	Humanised	Moderate
blinatumomab	Tumour antigen & T-cell (bispecific)	Dependent on targeted receptor and T-cell engagement	Murine	Highest
nivolumab	Immune system or checkpoint	Autoimmune—any system can be affected	Human	Lower
pembrolizumab	Immune system or checkpoint	Autoimmune—any system can be affected	Humanised	Moderate
****brentuximab vedotin**	Tumour antigen	Dependent on targeted receptor	Chimeric	High

**These are conjugated MABs and therefore assessment needs to also be completed based on the conjugation. Conjugated MABs are covered in our ADAC modules. These MABs are included here simply for practice in their nomenclature.

This resource is not designed as an exhaustive list. Always check the product information for the most up-to-date information.